162 related articles for article (PubMed ID: 38186937)
1. A Delphi study to determine the epidemiology and clinical management of patients treated with HDMTX who develop methotrexate (MTX) delayed elimination in France, Germany, Italy, and the UK.
Bielack S; Fox CP; Hoang-Xuan K; Giró-Perafita A; Rizzari C
Health Sci Rep; 2024 Jan; 7(1):e1749. PubMed ID: 38186937
[TBL] [Abstract][Full Text] [Related]
2. Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study.
Gros L; Roldán A; Cabero-Martínez A; Domínguez-Pinilla N; de la Fuente A; González-Barca E; Tasso M; Torrent M; Gallardo E; Del Cerro I; Giró-Perafita A; Badia X
J Oncol Pharm Pract; 2023 Jun; 29(4):794-801. PubMed ID: 35147457
[TBL] [Abstract][Full Text] [Related]
3. [Survey of Methotrexate Prescription and Blood Concentration in Patients Treated with High-Dose Methotrexate].
Kobayashi S; Yasu T; Momo K; Ohno N
Gan To Kagaku Ryoho; 2020 Jul; 47(7):1063-1067. PubMed ID: 32668853
[TBL] [Abstract][Full Text] [Related]
4. High-Dose Methotrexate in Pediatric Acute Lymphoblastic Leukemia: Predictors of Delayed Clearance and the Effect of Increased Hydration Rate on Methotrexate Clearance.
Chen AR; Wang YM; Lin M; Kuo DJ
Cureus; 2020 Jun; 12(6):e8674. PubMed ID: 32699674
[TBL] [Abstract][Full Text] [Related]
5. High-Dose Methotrexate: Nursing Considerations for Administration and Supportive Care.
Roche B; Clarke PA; Ford D; Collins Shaver S; Thompson J
Clin J Oncol Nurs; 2023 Jan; 27(1):47-54. PubMed ID: 37677820
[TBL] [Abstract][Full Text] [Related]
6. High dose methotrexate in adult Egyptian patients with hematological malignancies: impact of ABCB1 3435C > T rs1045642 and MTHFR 677C > T rs1801133 polymorphisms on toxicities and delayed elimination.
Ebid AIM; Hossam A; El Gammal MM; Soror S; Mangoud NOM; Mahmoud MA
J Chemother; 2022 Oct; 34(6):381-390. PubMed ID: 34895107
[TBL] [Abstract][Full Text] [Related]
7. Glucarpidase for the treatment of life-threatening methotrexate overdose.
Tuffaha HW; Al Omar S
Drugs Today (Barc); 2012 Nov; 48(11):705-11. PubMed ID: 23170306
[TBL] [Abstract][Full Text] [Related]
8. Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance.
Ramsey LB; Balis FM; O'Brien MM; Schmiegelow K; Pauley JL; Bleyer A; Widemann BC; Askenazi D; Bergeron S; Shirali A; Schwartz S; Vinks AA; Heldrup J
Oncologist; 2018 Jan; 23(1):52-61. PubMed ID: 29079637
[TBL] [Abstract][Full Text] [Related]
9. Outcomes Associated with Reducing the Urine Alkalinization Threshold in Patients Receiving High-Dose Methotrexate.
Drost SA; Wentzell JR; Giguère P; McLurg DL; Sabloff M; Kanji S; Nguyen TT
Pharmacotherapy; 2017 Jun; 37(6):684-691. PubMed ID: 28394433
[TBL] [Abstract][Full Text] [Related]
10. Charcoal Hemoperfusion for Methotrexate Toxicity: A Safe and Effective Life-Rescue Alternative When Glucarpidase Is Not Available.
Rosales A; Madrid A; Muñoz M; Dapena JL; Ariceta G
Front Pediatr; 2021; 9():635152. PubMed ID: 34490152
[No Abstract] [Full Text] [Related]
11. Preventing and Managing Toxicities of High-Dose Methotrexate.
Howard SC; McCormick J; Pui CH; Buddington RK; Harvey RD
Oncologist; 2016 Dec; 21(12):1471-1482. PubMed ID: 27496039
[TBL] [Abstract][Full Text] [Related]
12. Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury.
Heuschkel S; Kretschmann T; Teipel R; von Bonin S; Richter S; Quick S; Alakel N; Röllig C; Balaian E; Kroschinsky F; Knoth H; Bornhäuser M; von Bonin M
Cancer Chemother Pharmacol; 2022 Jan; 89(1):41-48. PubMed ID: 34669022
[TBL] [Abstract][Full Text] [Related]
13. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.
Widemann BC; Balis FM; Kim A; Boron M; Jayaprakash N; Shalabi A; O'Brien M; Eby M; Cole DE; Murphy RF; Fox E; Ivy P; Adamson PC
J Clin Oncol; 2010 Sep; 28(25):3979-86. PubMed ID: 20679598
[TBL] [Abstract][Full Text] [Related]
14. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
[TBL] [Abstract][Full Text] [Related]
15. The use of glucarpidase as a rescue therapy for high dose methotrexate toxicity - a review of pharmacological and clinical data.
Kielbowski K; Rosik J; Bakinowska E; Gromowska E; Ustianowski Ł; Szostak B; Pawlik A
Expert Opin Drug Metab Toxicol; 2023; 19(11):741-750. PubMed ID: 37846862
[TBL] [Abstract][Full Text] [Related]
16. Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate.
Barreto JN; Peterson KT; Barreto EF; Mara KC; Dierkhising RA; Leung N; Witzig TE; Thompson CA
Support Care Cancer; 2021 Sep; 29(9):5293-5301. PubMed ID: 33661366
[TBL] [Abstract][Full Text] [Related]
17. Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma.
Tsurusawa M; Gosho M; Mori T; Mitsui T; Sunami S; Kobayashi R; Fukano R; Tanaka F; Fujita N; Inada H; Koh K; Takimoto T; Saito A; Fujimoto J; Nakazawa A; Horibe K;
Pediatr Blood Cancer; 2015 Feb; 62(2):279-284. PubMed ID: 25359701
[TBL] [Abstract][Full Text] [Related]
18. Use of glucarpidase (carboxypeptidase-G2) in pediatric cancer patients: 11-year experience of a tertiary center.
Vila R; Rubio-San-Simón A; Zubiaur P; Navares-Gómez M; Gómez-Hernández P; Arce B; Madero L
EJHaem; 2023 Nov; 4(4):1052-1058. PubMed ID: 38024601
[TBL] [Abstract][Full Text] [Related]
19. Effective elimination of high-dose methotrexate by repeated hemodiafiltration and high-flux hemodialysis in patients with acute kidney injury.
Sakran R; Milo G; Jabareen A; Artul T; Haim N; Litvak M; Ringelstein-Harlev S; Horowitz N; Efrati E; Assady S; Kurnik D
J Oncol Pharm Pract; 2022 Mar; 28(2):508-515. PubMed ID: 34668443
[TBL] [Abstract][Full Text] [Related]
20. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
